Ma Dongliang, Yoon Su-In, Yang Chih-Hao, Marcy Guillaume, Zhao Na, Leong Wan-Ying, Ganapathy Vinu, Han Ju, Van Dongen Antonius M J, Hsu Kuei-Sen, Ming Guo-Li, Augustine George J, Goh Eyleen L K
Programme in Neuroscience and Behavioral Disorders, Duke-NUS Graduate Medical School, Singapore, Singapore.
Neurotherapeutics. 2015 Apr;12(2):477-90. doi: 10.1007/s13311-015-0343-0.
Rett syndrome is a neurodevelopmental disorder that usually arises from mutations or deletions in methyl-CpG binding protein 2 (MeCP2), a transcriptional regulator that affects neuronal development and maturation without causing cell loss. Here, we show that silencing of MeCP2 decreased neurite arborization and synaptogenesis in cultured hippocampal neurons from rat fetal brains. These structural defects were associated with alterations in synaptic transmission and neural network activity. Similar retardation of dendritic growth was also observed in MeCP2-deficient newborn granule cells in the dentate gyrus of adult mouse brains in vivo, demonstrating direct and cell-autonomous effects on individual neurons. These defects, caused by MeCP2 deficiency, were reversed by treatment with the US Food and Drug Administration-approved drug, pentobarbital, in vitro and in vivo, possibly caused by modulation of γ-aminobutyric acid signaling. The results indicate that drugs modulating γ-aminobutyric acid signaling are potential therapeutics for Rett syndrome.
雷特综合征是一种神经发育障碍疾病,通常由甲基CpG结合蛋白2(MeCP2)的突变或缺失引起,MeCP2是一种转录调节因子,可影响神经元发育和成熟,而不会导致细胞丢失。在此,我们表明,沉默MeCP2会减少大鼠胎脑海马神经元培养物中的神经突分支和突触形成。这些结构缺陷与突触传递和神经网络活动的改变有关。在成年小鼠脑齿状回中缺乏MeCP2的新生颗粒细胞中,也观察到了类似的树突生长迟缓,这证明了对单个神经元的直接和细胞自主作用。这些由MeCP2缺乏引起的缺陷,在体外和体内通过美国食品药品监督管理局批准的药物戊巴比妥治疗得以逆转,这可能是由γ-氨基丁酸信号调节所致。结果表明,调节γ-氨基丁酸信号的药物是雷特综合征的潜在治疗方法。